Optimi Health Corp. OPTH

Optimi Health Corp. announced completion and quality release of a 5 mg natural psilocybin capsule batch produced in-house at its cGMP facility in Princeton, BC, under Health Canada-approved Drug Establishment Licence. The batch will supply a Health Canada-approved Phase 2 trial for major depressive disorder and Optimi's Australian clinical customers. The Phase 2 study is multisite, open-label, and aims to enroll up to 200 participants; dosing is expected by the end of 2027. Data from the trial are intended to support regulatory registration in Canada and other jurisdictions. The same batch will also be used for Australian clinics under the Therapeutic Goods Administration Authorized Prescriber Scheme, with reimbursement from public and private payers. More than 750 clinicians have completed Mind Medicine Australia's certificate in psychedelic-assisted therapies; Optimi reports no serious adverse events since commercial supply began in 2025. CEO Dane Stevens calls it 'one batch, two indications.' In-house, dual-use batch supports both a pivotal trial and commercial supply, potentially accelerating regulatory progress and strengthening market position.

Optimi Health Corp announced it has completed a production batch of 5-mg naturally derived psilocybin for its Phase 2 MDD trial. The milestone signals progress in manufacturing for the psychedelic-assisted program and supports trial readiness, highlighting the company's ability to produce the drug component at scale as it advances toward Phase 2 evaluation for major depressive disorder. Advances manufacturing for a Phase 2 psilocybin program, supporting trial timelines and potential investor confidence.

Optimi Health Corp. appointed Michael Blough, Ph.D., as Chief Clinical Development Officer to oversee its clinical development program, including a planned Phase 2 psilocybin-assisted psychotherapy trial for major depressive disorder and a Phase 3 MDMA-assisted psychotherapy trial for PTSD. Blough, who has more than 20 years of experience directing Health Canada-authorized clinical trials, will manage protocol execution, site activation, Health Canada interactions, and the data package intended to support product registrations. The role expands two trials that Optimi expects to begin enrolling patients next year. Optimi, a GMP-certified Canadian manufacturer of MDMA and botanical psilocybin, supplies regulated drug products for clinical and therapeutic programs internationally and operates in Canada under the Special Access Program. Assembles senior clinical development leadership to advance two pivotal psychedelic trials, potentially influencing regulatory timelines and future growth.

Optimi Health advances its MDMA trial as the FDA holds a hearing on psychedelics for PTSD treatment, following Elon Musk's prior comments on the potential benefits. FDA hearing on MDMA for PTSD combined with Optimi trial progress signals likely regulatory shifts and boosted market positioning for the company.

Optimi Health expands its clinical program by initiating a Phase 3 trial of MDMA-assisted therapy for post-traumatic stress disorder. Phase 3 trial start for MDMA therapy in PTSD marks major clinical progress that can shift company trajectory and investor sentiment.

Optimi Health Corp. (OPTH) initiates Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder. Phase 2 trial start marks key pipeline advance likely to drive valuation gains and strategic positioning.

Optimi Health establishes a $100 million equity facility to advance psychedelic commercialization. Large equity facility supplies capital to accelerate Optimi Health commercialization and growth trajectory.

Optimi Health Corp. establishes a discretionary equity facility. Discretionary equity facility enables flexible capital access with potential effects on financial strategy and operations.

Optimi Health Corp. completed psilocybin export to Australia for patients with treatment-resistant depression. Export marks first international psilocybin shipment opening Australian market access and regulatory validation.

Optimi Health Corp. completed export of psilocybin to Australia for patients with treatment-resistant depression. Psilocybin export to Australia opens new revenue opportunities for Optimi Health.

Optimi Health Corp. launches standardized microdose psilocybin products for clinical research. Product launch opens clinical research revenue channels and advances psilocybin positioning.

Optimi Health Corp. launches standardized microdose psilocybin products for clinical research. Product launch advances clinical research capabilities and expands market positioning in psilocybin sector.

Optimi Health Corp. advances ibogaine initiative that could create new growth channel for the company. Ibogaine initiative opens new growth channel and can significantly shift company trajectory.

Optimi Health Corp. completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial. First psilocybin export to UK enables Phase 2 trials and expands international operations.

Optimi Health completed the first export of psilocybin to the United Kingdom for a Phase 2 clinical trial. First psilocybin export to UK for Phase 2 trial advances Optimi's international regulatory and clinical milestones.

Optimi Health secured ibogaine supply and commenced finished drug product development. Securing ibogaine supply and starting finished drug product development advances Optimi Health core pipeline and market positioning.

Optimi Health completes commercial psilocybin production for treatment-resistant depression in Australia. Commercial psilocybin production completion enables supply to Australia and supports revenue growth plus market expansion.

Optimi Health Corp. (OPTH) shares rose 2.5% after completing a commercial production run of 5mg psilocybin. Completion of commercial 5mg psilocybin production advances operational readiness for revenue generation.

Optimi Health (OPTH) expands psychedelic therapy operations in Australia after TGA updates regulatory framework. TGA framework update enables Optimi Health psychedelic therapy expansion in Australia with significant trajectory impact.

Optimi Health gains from Australia's updated authorized prescriber framework that expands access to psychedelic-assisted therapy. Australia's expanded access framework directly boosts Optimi Health's market opportunities in psychedelic therapy.

Optimi Health welcomes expanded psychedelic-assisted therapy access under Australia's updated authorized prescriber framework. Australia's updated prescriber framework expands psychedelic therapy access and directly supports Optimi Health's market growth.

Optimi Health Corp. produced the highest-purity natural psilocybin extract achieved to date. Highest-purity psilocybin extract advances product innovation and strengthens competitive positioning in psychedelics market.

Optimi Health Corp. closed an oversubscribed US$15 million public offering. Oversubscribed 15 million dollar public offering supplies major new capital to Optimi Health Corp. supporting operations and growth plans.

SRx Health invested in Optimi Health Corp. (OPTH), a psychedelic drug company that recently went public, based on factors supporting the decision. SRx Health investment delivers capital and external validation to Optimi Health Corp. with moderate effects on operations and sentiment.